Observational studyThe Journal of antimicrobial chemotherapy2025
Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments.
Observational study in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
BACKGROUND AND
objectivesThe management of SARS-CoV-2-infected patients with haematological malignancies and active disease is challenging, particularly in determining when to restart cancer therapy. This study evaluated the time to resumption of haematological therapy in adults with active haematological malignancies affected by SARS-CoV-2 infection and treated with either single-drug regimens (SR) or combined regimens (CR). MATERIALS AND
methodsAn observational cohort study was set up including patients with active haematological disease treated for SARS-CoV-2 infection between January 2022 and December 2023. Kaplan-Meier estimates and Cox regression models were fitted to analyse the time to restarting anti-cancer therapy and factors associated with resumption within 60 days.
resultsOf the 79 patients included, 68 (86%) received SR, and 11 (14%) received CR. Patients on CR were more likely to require oxygen support (P = 0.006) and to have additional causes of immunosuppression (P = <0.001) compared with those on SR. The median time to restart therapy did not significantly differ between groups (38 days [IQR 21-70] for SR versus 30 days [IQR 18-77] for CR; P = 0.46). By Fine-Gray competing risk regression analysis, pneumonia (HR 0.36, 95% CI 0.18-0.71), but not CR (HR 0.62, 95% CI 0.23-1.69), independently reduced the likelihood of restarting therapy within 60 days of SARS-CoV-2 diagnosis.
conclusionsCombination regimens for SARS-CoV-2 did not affect the time to restart haematological therapy, whereas the occurrence of pneumonia was associated with delayed resumption of chemotherapy. The real benefit of COVID-19 combination therapy in the setting of haematologic malignancies, particularly for early treatment strategies, should be referred to the evidence from randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.